S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:CNCE

Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

$6.13
-0.02 (-0.33%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.91
$6.17
50-Day Range
$4.09
$6.36
52-Week Range
$2.57
$6.88
Volume
1.04 million shs
Average Volume
462,843 shs
Market Capitalization
$222.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Concert Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
95.8% Upside
$12.00 Price Target
Short Interest
Healthy
3.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.57mentions of Concert Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Acquiring Shares
$49,998 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.47) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

171st out of 1,283 stocks

Pharmaceutical Preparations Industry

69th out of 615 stocks

CNCE stock logo

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Concert Pharmaceuticals in a research note on Wednesday, June 15th. They set a "hold" rating on the stock.

Concert Pharmaceuticals Stock Performance

CNCE opened at $6.13 on Friday. The company's fifty day moving average price is $4.85 and its two-hundred day moving average price is $3.89. Concert Pharmaceuticals has a 1-year low of $2.57 and a 1-year high of $6.88.

Concert Pharmaceuticals (NASDAQ:CNCE - Get Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.07). Concert Pharmaceuticals had a negative net margin of 245.72% and a negative return on equity of 125.90%. During the same quarter in the previous year, the company posted ($0.67) earnings per share. Equities analysts forecast that Concert Pharmaceuticals will post -3.47 earnings per share for the current year.

Insider Activity

In related news, Director Heek Christi Van acquired 10,526 shares of the firm's stock in a transaction that occurred on Monday, June 6th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $49,998.50. Following the completion of the acquisition, the director now owns 25,651 shares of the company's stock, valued at approximately $121,842.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.00% of the stock is currently owned by corporate insiders.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Recap: Concert Pharma Q2 Earnings
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Concert Pharmaceuticals: A Balanced Risk/Reward
See More Headlines
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Company Calendar

Last Earnings
11/09/2021
Today
8/07/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+95.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-80,050,000.00
Net Margins
-245.72%
Pretax Margin
-291.99%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.24 per share

Miscellaneous

Free Float
32,333,000
Market Cap
$222.70 million
Optionable
Optionable
Beta
0.69














CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Concert Pharmaceuticals stock.
View analyst ratings for Concert Pharmaceuticals
or view top-rated stocks.

What is Concert Pharmaceuticals' stock price forecast for 2022?

3 Wall Street analysts have issued twelve-month price objectives for Concert Pharmaceuticals' stock. Their CNCE stock forecasts range from $9.00 to $17.00. On average, they predict Concert Pharmaceuticals' stock price to reach $12.00 in the next year. This suggests a possible upside of 95.8% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Concert Pharmaceuticals' stock performed in 2022?

Concert Pharmaceuticals' stock was trading at $3.15 at the beginning of the year. Since then, CNCE shares have increased by 94.6% and is now trading at $6.13.
View the best growth stocks for 2022 here
.

Are investors shorting Concert Pharmaceuticals?

Concert Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 1,100,000 shares, an increase of 16.5% from the June 30th total of 944,600 shares. Based on an average daily volume of 818,800 shares, the short-interest ratio is presently 1.3 days.
View Concert Pharmaceuticals' Short Interest
.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our earnings forecast for Concert Pharmaceuticals
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $0.25 million. Concert Pharmaceuticals had a negative net margin of 245.72% and a negative trailing twelve-month return on equity of 125.90%. During the same quarter in the previous year, the firm posted ($0.60) earnings per share.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals CEO Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among Concert Pharmaceuticals' employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.51%), Connor Clark & Lunn Investment Management Ltd. (0.83%) and Black Diamond Financial LLC (0.19%). Company insiders that own Concert Pharmaceuticals stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals
.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $6.13.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $222.70 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis.

How many employees does Concert Pharmaceuticals have?

Concert Pharmaceuticals employs 64 workers across the globe.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for Concert Pharmaceuticals is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.

This page (NASDAQ:CNCE) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.